Takeda could acquire next-generation immunotherapies ... The company has had success with Ninlaro in multiple myeloma and its antibody-drug conjugate Adcetris in blood cancers including classical ...

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...

Another candidate for AL amyloidosis – Takeda's Ninlaro (ixazomib) – flunked the phase 3 TOURMALINE-AL1 trial in 2019, but was subsequently shown to have had "clinically meaningful" effects on ...

Ninlaro O (Ixazomib Citrate) Takeda Canada Inc - Ninlaro is used in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

Takeda’s (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit and chair of the Plasma Protein ...

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

January 30, 2025 Drugmaker Takeda's CEO Weber to step down, raises profit forecast Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other Japanese stocks. As the dangers of natural disasters increase and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...